News for CEL-SCI Corporation (CVM)

CEL-SCI Corporation (CVM) closes a $5.7 million offering for 1.5 million shares priced at $3.82 each. Proceeds will support the development of Multikine

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday. Shares of Ultragenyx Pharmaceutical Inc. RARE fell sharpl...

Shares of Datavault AI Inc. DVLT rose sharply in today's pre-market trading after the company entered into a licensing deal with IBM for program subscriptions. ...

CEL-SCI Corp aims to raise $5.7 million through a stock offering. Multikine development, corporate activities, and working capital are key focus areas f

CEL-SCI Corporation (CVM) announces a $5.7 million stock offering. Shares priced at $3.82 each, with closing anticipated on July 14, 2025. Proceeds a

The FDA approved Merck's Keytruda for head and neck cancer patients with PD-L1 positive tumors. CEL-SCI's Multikine shows promising results for PD-L1 negati

CEL-SCI Corporation (CVM) successfully closes its public offering of 2 million common stock shares at $2.50 each, raising $5 million in gross proceeds.The comp

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 0.2% on Thursday. The Dow traded up 0.17% to 41,932.94 while the NASD...

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the D...

California-based Navitas Semiconductor Corporation (NVTS) is up over 14 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in xxday's pre-market trading.

CEL-SCI Corporation (CVM) announces the pricing of an underwritten public offering of 2 million shares at $2.50 per share. Gross proceeds expected at $5

CEL-SCI Corporation (CVM) announces a proposed public offering of common stock and/or pre-funded warrants. The offering proceeds will support the develo

CEL-SCI Corporation (CVM) submits Breakthrough Medicine Designation application for its cancer therapy, Multikine, in Saudi Arabia. The Saudi Food and D

CEL-SCI Corporation (CVM) has announced a significant development following its recent annual shareholder meeting. The company's board of directors approved a 1

CEL-SCI Corporation (CVM) announces a 1-for-30 stock combination effective May 20, 2025. The combination aims to increase the share price to attract mor

CEL-SCI Corporation (CVM) plans to file for regulatory approval of Multikine in Saudi Arabia. The company reported a net loss of $6.6 million for the fi

CEL-SCI Corporation (CVM) to file for regulatory approval of Multikine in Saudi Arabia with expected response in 60 days. Exploring partnerships for Mul

PR NewswireVANCOUVER, BC, April 14, 2025 Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, April 14, 2025 /PRNewswire

Shares of Harrow, Inc. HROW rose sharply in pre-market trading after the company reported fourth quarter and year-end 2024 unaudited preliminary financial resul...